Gilead Sciences Inc (GILD) 86.25 $GILD
Top 7 Research Reports for July 11, 2016
Sheraz Mian - Zacks Investment Research - Mon Jul 11, 12:50PM CDT
Top 7 Research Reports for July 11, 2016
GILD: 86.25 (-0.30), MO: 69.87 (+0.04), PG: 85.75 (-0.02), SO: 53.79 (-0.35), NVS: 82.31 (+0.18)
Ligand (LGND) Signs Deal with Gilead for OmniAb Technology
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 10:00AM CDT
Ligand (LGND) announced that it has entered into a worldwide license agreement with Gilead (GILD) for OmniAb Technology.
EBS: 30.47 (+0.43), INVA: 11.77 (+0.13), GILD: 86.25 (-0.30), LGND: 126.76 (+0.90)
Gilead's Pan-Genotypic HCV Drug Epclusa Gains EU Approval
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 9:23AM CDT
Gilead Sciences' (GILD) first pan-genotypic, single-tablet regimen, Epclusa, gained EU approval for the treatment of all genotypes of chronic hepatitis C.
INVA: 11.77 (+0.13), FCSC: 1.18 (-0.02), GILD: 86.25 (-0.30), MRK: 59.34 (-0.01)
Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 62.23 (+0.13), BIIB: 252.54 (+1.24), VRTX: 90.10 (+1.14), GILD: 86.25 (-0.30), UNH: 140.32 (-0.95), MRK: 59.34 (-0.01), ALXN: 125.30 (+0.88), XOM: 93.89 (+0.35), CVX: 105.39 (+0.62), REGN: 375.74 (-2.61), CELG: 103.41 (-1.62)
After Yesterday's Rally of 1.78% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jul 06, 12:03PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $83.33 to a high of $85.44. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $85.30 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 86.25 (-0.30)
The Zacks Analyst Blog Highlights: Gilead, Regulus, AbbVie, The Medicines and GW Pharma
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead, Regulus, AbbVie, The Medicines and GW Pharma
GWPH: 96.35 (+1.52), MDCO: 36.19 (+1.29), GILD: 86.25 (-0.30), RGLS: 3.55 (+0.05), ABBV: 64.35 (+0.19)
Gilead Sciences Stock Is Poised To Soar Due To New HCV Drug Approval
Arie Goren - Amigobulls - Thu Jun 30, 3:58AM CDT
The average target price of the top analysts for Gilead Stock is at $107.50, an upside of 30.6% from its June 28 close price, which appears reasonable.
GILD: 86.25 (-0.30)
Top 6 Research Reports for June 29, 2016
Sheraz Mian - Zacks Investment Research - Wed Jun 29, 1:35PM CDT
Top 6 Research Reports for June 29, 2016
BCS: 7.67 (+0.35), GILD: 86.25 (-0.30), EXPE: 111.28 (+1.85), KHC: 89.84 (-0.01), AMGN: 160.18 (-0.92), UPS: 110.01 (+0.49)
Biotech Stock Roundup: Gilead Gets FDA Nod for HCV Drug, Regulus Hit by Clinical Hold
Arpita Dutt - Zacks Investment Research - Wed Jun 29, 1:23PM CDT
Most biotech stocks were down reflecting uncertainty regarding the impact of Brexit on the sector especially companies which generate significant sales in the EU.
GWPH: 96.35 (+1.52), GILD: 86.25 (-0.30), MDCO: 36.19 (+1.29), ALXN: 125.30 (+0.88), RGLS: 3.55 (+0.05), ABBV: 64.35 (+0.19), XNCR: 17.93 (-0.69)
FDA approves first pill to treat all forms of hepatitis C
By MATTHEW PERRONE - AP - Tue Jun 28, 3:19PM CDT
WASHINGTON (AP) — Federal health officials on Tuesday approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus.
GILD: 86.25 (-0.30), MRK: 59.34 (-0.01), BMY: 75.39 (+0.11)
Why Is Gilead Sciences (GILD) Stock Gaining Today?
Ryan McQueeney - Zacks Investment Research - Tue Jun 28, 11:59AM CDT
Gild Sciences (GILD) gained nearly 3.5% in morning trading today following the approval of its new hepatitis C drug.
GILD: 86.25 (-0.30), ABBV: 64.35 (+0.19)
U.S. Food and Drug Administration Approves Gilead's Epclusa(R) (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
BusinessWire - Tue Jun 28, 9:25AM CDT
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Epclusa(R) (sofosbuvir 400 mg/velpatasvir 100 mg), the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for ribavirin. Epclusa for 12 weeks was approved in patients without cirrhosis or with compensated cirrhosis (Child-Pugh A), and in combination with ribavirin (RBV) for patients with decompensated cirrhosis (Child-Pugh B or C).
GILD: 86.25 (-0.30)
Gilead Sciences Set to Possibly Rebound After Yesterday's Selloff of 1.58%
Comtex SmarTrend(R) - Mon Jun 27, 12:22PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $78.70 to a high of $80.47. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $80.22 on volume of 4.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 86.25 (-0.30)
Gilead's (GILD) HIV Treatment Odefsey Gains Approval in EU
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 9:08AM CDT
Gilead Sciences' (GILD) once-daily single tablet regimen Odefsey gained EU approval for the treatment of HIV-1 infection in certain patients.
JNJ: 122.93 (+0.08), GILD: 86.25 (-0.30), ANIP: 55.38 (-1.13), RTRX: 18.47 (-0.18)
European Commission Grants Marketing Authorization for Gilead's Single Tablet Regimen Odefsey(R) (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV
BusinessWire - Thu Jun 23, 6:53AM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for the once-daily single tablet regimen (STR) Odefsey(R) (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients. Odefsey combines Gilead's emtricitabine and tenofovir alafenamide (marketed as Descovy(R)) with rilpivirine, marketed by Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Following the approval of Genvoya in November 2015, Odefsey is Gilead's second STR based on the Descovy backbone to receive marketing authorization in the European Union and is currently the smallest pill of any STR for the treatment of HIV.
JNJ: 122.93 (+0.08), GILD: 86.25 (-0.30)
Stock Market News for June 22, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:10AM CDT
Benchmarks ended slightly higher on Tuesday as the latest Brexit polls tilted slightly in favor of the ‘remain’ camp
JNJ: 122.93 (+0.08), MU: 12.64 (+0.02), PXD: 153.00 (-0.72), GILD: 86.25 (-0.30), EOG: 82.90 (+0.36), AMGN: 160.18 (-0.92), ABBV: 64.35 (+0.19), GOOGL: 727.20 (+9.42), CVX: 105.39 (+0.62), MSFT: 52.59 (+0.29)
SmarTrend Watching for Potential Rebound in Shares of Gilead Sciences After 1.25% Loss
Comtex SmarTrend(R) - Tue Jun 21, 12:03PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $81.70 to a high of $83.44. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $82.23 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 86.25 (-0.30)
Gilead Presents Favorable Preliminary Bictegravir HIV Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:21AM CDT
Gilead Sciences (GILD) presented encouraging preliminary data from four pre-clinical and phase I studies evaluating bictegravir for the treatment of HIV.
GILD: 86.25 (-0.30), ANIP: 55.38 (-1.13), RTRX: 18.47 (-0.18), BMY: 75.39 (+0.11)
Roger Ulrich Joins Board of Remedy Pharmaceuticals
BusinessWire - Tue Jun 21, 9:00AM CDT
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that Roger Ulrich has joined the company's board of directors.
GILD: 86.25 (-0.30), PFE: 36.15 (+0.03), MRK: 59.34 (-0.01), AZN: 29.97 (-0.14)
New Strong Sell Stocks for June 21st
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:53AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
ECPG: 23.77 (+0.38), GILD: 86.25 (-0.30), FII: 29.35 (+0.54), FRAN: 12.43 (+0.58), WMS: 28.15 (+0.29)
Top 7 Research Reports for July 11, 2016
Sheraz Mian - Zacks Investment Research - Mon Jul 11, 12:50PM CDT
Top 7 Research Reports for July 11, 2016
GILD: 86.25 (-0.30), MO: 69.87 (+0.04), PG: 85.75 (-0.02), SO: 53.79 (-0.35), NVS: 82.31 (+0.18)
Ligand (LGND) Signs Deal with Gilead for OmniAb Technology
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 10:00AM CDT
Ligand (LGND) announced that it has entered into a worldwide license agreement with Gilead (GILD) for OmniAb Technology.
EBS: 30.47 (+0.43), INVA: 11.77 (+0.13), GILD: 86.25 (-0.30), LGND: 126.76 (+0.90)
Gilead's Pan-Genotypic HCV Drug Epclusa Gains EU Approval
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 9:23AM CDT
Gilead Sciences' (GILD) first pan-genotypic, single-tablet regimen, Epclusa, gained EU approval for the treatment of all genotypes of chronic hepatitis C.
INVA: 11.77 (+0.13), FCSC: 1.18 (-0.02), GILD: 86.25 (-0.30), MRK: 59.34 (-0.01)
Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 62.23 (+0.13), BIIB: 252.54 (+1.24), VRTX: 90.10 (+1.14), GILD: 86.25 (-0.30), UNH: 140.32 (-0.95), MRK: 59.34 (-0.01), ALXN: 125.30 (+0.88), XOM: 93.89 (+0.35), CVX: 105.39 (+0.62), REGN: 375.74 (-2.61), CELG: 103.41 (-1.62)
After Yesterday's Rally of 1.78% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jul 06, 12:03PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $83.33 to a high of $85.44. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $85.30 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GILD: 86.25 (-0.30)
The Zacks Analyst Blog Highlights: Gilead, Regulus, AbbVie, The Medicines and GW Pharma
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead, Regulus, AbbVie, The Medicines and GW Pharma
GWPH: 96.35 (+1.52), MDCO: 36.19 (+1.29), GILD: 86.25 (-0.30), RGLS: 3.55 (+0.05), ABBV: 64.35 (+0.19)
Gilead Sciences Stock Is Poised To Soar Due To New HCV Drug Approval
Arie Goren - Amigobulls - Thu Jun 30, 3:58AM CDT
The average target price of the top analysts for Gilead Stock is at $107.50, an upside of 30.6% from its June 28 close price, which appears reasonable.
GILD: 86.25 (-0.30)
Top 6 Research Reports for June 29, 2016
Sheraz Mian - Zacks Investment Research - Wed Jun 29, 1:35PM CDT
Top 6 Research Reports for June 29, 2016
BCS: 7.67 (+0.35), GILD: 86.25 (-0.30), EXPE: 111.28 (+1.85), KHC: 89.84 (-0.01), AMGN: 160.18 (-0.92), UPS: 110.01 (+0.49)
Biotech Stock Roundup: Gilead Gets FDA Nod for HCV Drug, Regulus Hit by Clinical Hold
Arpita Dutt - Zacks Investment Research - Wed Jun 29, 1:23PM CDT
Most biotech stocks were down reflecting uncertainty regarding the impact of Brexit on the sector especially companies which generate significant sales in the EU.
GWPH: 96.35 (+1.52), GILD: 86.25 (-0.30), MDCO: 36.19 (+1.29), ALXN: 125.30 (+0.88), RGLS: 3.55 (+0.05), ABBV: 64.35 (+0.19), XNCR: 17.93 (-0.69)
FDA approves first pill to treat all forms of hepatitis C
By MATTHEW PERRONE - AP - Tue Jun 28, 3:19PM CDT
WASHINGTON (AP) — Federal health officials on Tuesday approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus.
GILD: 86.25 (-0.30), MRK: 59.34 (-0.01), BMY: 75.39 (+0.11)
Why Is Gilead Sciences (GILD) Stock Gaining Today?
Ryan McQueeney - Zacks Investment Research - Tue Jun 28, 11:59AM CDT
Gild Sciences (GILD) gained nearly 3.5% in morning trading today following the approval of its new hepatitis C drug.
GILD: 86.25 (-0.30), ABBV: 64.35 (+0.19)
U.S. Food and Drug Administration Approves Gilead's Epclusa(R) (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
BusinessWire - Tue Jun 28, 9:25AM CDT
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Epclusa(R) (sofosbuvir 400 mg/velpatasvir 100 mg), the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for ribavirin. Epclusa for 12 weeks was approved in patients without cirrhosis or with compensated cirrhosis (Child-Pugh A), and in combination with ribavirin (RBV) for patients with decompensated cirrhosis (Child-Pugh B or C).
GILD: 86.25 (-0.30)
Gilead Sciences Set to Possibly Rebound After Yesterday's Selloff of 1.58%
Comtex SmarTrend(R) - Mon Jun 27, 12:22PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $78.70 to a high of $80.47. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $80.22 on volume of 4.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 86.25 (-0.30)
Gilead's (GILD) HIV Treatment Odefsey Gains Approval in EU
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 9:08AM CDT
Gilead Sciences' (GILD) once-daily single tablet regimen Odefsey gained EU approval for the treatment of HIV-1 infection in certain patients.
JNJ: 122.93 (+0.08), GILD: 86.25 (-0.30), ANIP: 55.38 (-1.13), RTRX: 18.47 (-0.18)
European Commission Grants Marketing Authorization for Gilead's Single Tablet Regimen Odefsey(R) (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV
BusinessWire - Thu Jun 23, 6:53AM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for the once-daily single tablet regimen (STR) Odefsey(R) (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients. Odefsey combines Gilead's emtricitabine and tenofovir alafenamide (marketed as Descovy(R)) with rilpivirine, marketed by Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Following the approval of Genvoya in November 2015, Odefsey is Gilead's second STR based on the Descovy backbone to receive marketing authorization in the European Union and is currently the smallest pill of any STR for the treatment of HIV.
JNJ: 122.93 (+0.08), GILD: 86.25 (-0.30)
Stock Market News for June 22, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:10AM CDT
Benchmarks ended slightly higher on Tuesday as the latest Brexit polls tilted slightly in favor of the ‘remain’ camp
JNJ: 122.93 (+0.08), MU: 12.64 (+0.02), PXD: 153.00 (-0.72), GILD: 86.25 (-0.30), EOG: 82.90 (+0.36), AMGN: 160.18 (-0.92), ABBV: 64.35 (+0.19), GOOGL: 727.20 (+9.42), CVX: 105.39 (+0.62), MSFT: 52.59 (+0.29)
SmarTrend Watching for Potential Rebound in Shares of Gilead Sciences After 1.25% Loss
Comtex SmarTrend(R) - Tue Jun 21, 12:03PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $81.70 to a high of $83.44. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $82.23 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 86.25 (-0.30)
Gilead Presents Favorable Preliminary Bictegravir HIV Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:21AM CDT
Gilead Sciences (GILD) presented encouraging preliminary data from four pre-clinical and phase I studies evaluating bictegravir for the treatment of HIV.
GILD: 86.25 (-0.30), ANIP: 55.38 (-1.13), RTRX: 18.47 (-0.18), BMY: 75.39 (+0.11)
Roger Ulrich Joins Board of Remedy Pharmaceuticals
BusinessWire - Tue Jun 21, 9:00AM CDT
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that Roger Ulrich has joined the company's board of directors.
GILD: 86.25 (-0.30), PFE: 36.15 (+0.03), MRK: 59.34 (-0.01), AZN: 29.97 (-0.14)
New Strong Sell Stocks for June 21st
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:53AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
ECPG: 23.77 (+0.38), GILD: 86.25 (-0.30), FII: 29.35 (+0.54), FRAN: 12.43 (+0.58), WMS: 28.15 (+0.29)
